Comparing Evofem Biosciences (NASDAQ:EVFM) and AEON Biopharma (NASDAQ:AEON)

Evofem Biosciences (NASDAQ:EVFM) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional and Insider Ownership

0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 0.0% of Evofem Biosciences shares are owned by insiders. Comparatively, 9.4% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Evofem Biosciences and AEON Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evofem Biosciences	-46.42%	-91.97%	-61.93%
AEON Biopharma	N/A	N/A	-994.63%

Risk & Volatility

Evofem Biosciences has a beta of -1.32, meaning that its stock price is 232% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Evofem Biosciences and AEON Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evofem Biosciences	0	0	0	0	0.00
AEON Biopharma	0	1	1	1	3.00

Earnings & Valuation

This table compares Evofem Biosciences and AEON Biopharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evofem Biosciences	$11.39 million	0.08	$52.98 million	($0.07)	-0.10
AEON Biopharma	N/A	N/A	-$36.63 million	($5.00)	-0.15

Evofem Biosciences has higher revenue and earnings than AEON Biopharma. AEON Biopharma is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

AEON Biopharma beats Evofem Biosciences on 9 of the 13 factors compared between the two stocks.

About Evofem Biosciences

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.